Anemia Management in CKD Stage 3a

Understanding Anemia in CKD Stage 3a

Erythropoietin deficiency is the fundamental driver of anemia in CKD, as failing kidneys cannot produce adequate amounts of this hormone needed to stimulate red blood cell production in bone marrow, leading to apoptotic collapse of early erythropoiesis, particularly when combined with other factors like functional iron deficiency 1, 2
The American Journal of Kidney Diseases suggests that iron deficiency has been shown to be present in 25% to 37.5% of patients presenting with anemia of CKD, and absolute iron deficiency is defined as TSAT ≤20% and ferritin ≤100 ng/mL for non-dialysis patients 3

The American Journal of Kidney Diseases recommends requesting complete iron panel including TSAT calculation, as serum iron alone is insufficient, and higher values of TSAT and serum ferritin are necessary to achieve an erythropoietic response prior to initiation of erythropoietin therapy 4, 3
Kidney International Supplements suggests requesting reticulocyte count with reticulocyte index to assess bone marrow response appropriateness, and a low reticulocyte index despite anemia indicates an inappropriate bone marrow response 2, 5

The American Journal of Kidney Diseases and Praxis Medical Insights recommend that iron supplementation should be initiated before considering erythropoietin therapy, as iron demands frequently exceed availability during erythropoietin treatment, and adequate iron stores are required to support accelerated erythropoiesis stimulated by erythropoietin 1, 3
Kidney International Supplements suggests that if iron repletion alone is insufficient after 1-3 months, erythropoietin-stimulating agents may be indicated, but adequate iron stores are required to support accelerated erythropoiesis stimulated by erythropoietin 2, 3

Kidney International recommends a cardiology-nephrology collaboration for cardiorenal syndrome, as managing the inflammation and hemodynamic issues will help address the anemia, and hematology consultation is reasonable given the complexity of the case with multiple contributing factors 2, 6

Low reticulocyte hemoglobin (Ret-He) occurs when inflammation upregulates hepcidin, trapping iron in macrophages and creating functional iron deficiency for erythropoiesis despite normal or elevated ferritin levels, as noted by the Journal of Crohn's and Colitis 7
If ferritin ≤100 ng/mL and TSAT ≤20%, absolute iron deficiency is indicated, and iron supplementation should be initiated immediately, according to the Journal of Crohn's and Colitis 7
If ferritin >100 μg/L but TSAT <20% with elevated CRP, anemia of chronic disease with functional iron deficiency is suggested, and iron supplementation is still recommended, as stated by the Journal of Crohn's and Colitis 7

Low Ret-He mandates iron supplementation before considering erythropoietin therapy, as adequate iron stores are required to support accelerated erythropoiesis stimulated by erythropoietin, with a goal of normalizing both hemoglobin levels and iron stores, and an acceptable response being hemoglobin increase of at least 2 g/dL within 4 weeks, as recommended by the Journal of Crohn's and Colitis 7